You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
PCSK9 inhibition - a novel mechanism to treat lipid disorders?
|
|---|---|
| Published in |
Current Pharmaceutical Design, January 2013
|
| DOI | 10.2174/13816128113199990303 |
| Pubmed ID | |
| Authors |
Maciej Banach, Manfredi Rizzo, Milan Obradovic, Giuseppe Montalto, Jacek Rysz, Dimitri P Mikhailidis, Esma R Isenovic |
| Abstract |
Plasma low-density lipoprotein cholesterol (LDL-C) is one of the biomarkers of cardiovascular disease (CVD) risk. LDL is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the LDLR. PCSK9 inhibition is attractive as a new strategy for lowering LDL-C levels, especially in combination with lipid lowering drugs such as statins. We review data from the available studies which focus on PCSK9 as a potential target in the treatment of hyperlipidemia. Further studies are still necessary to investigate the potential underlying mechanisms involved. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 19% |
| Student > Bachelor | 5 | 16% |
| Researcher | 5 | 16% |
| Student > Postgraduate | 3 | 9% |
| Professor | 3 | 9% |
| Other | 7 | 22% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 5 | 16% |
| Agricultural and Biological Sciences | 3 | 9% |
| Nursing and Health Professions | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2015.
All research outputs
#15,366,818
of 22,860,626 outputs
Outputs from Current Pharmaceutical Design
#2,312
of 3,526 outputs
Outputs of similar age
#182,009
of 281,249 outputs
Outputs of similar age from Current Pharmaceutical Design
#57
of 97 outputs
Altmetric has tracked 22,860,626 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,526 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,249 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.